FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for determination of indications for photodynamic therapy in case of chronic central serous chorioretinopathy (CCSC). For this purpose level of noradrenalin and adrenalin is measured in blood serum. If value of noradrenalin is 550 pg/ml and higher and/or value of adrenalin 95 pg/ml, photodynamic therapy is carried out.
EFFECT: method ensures adequate selection of treatment tactics in said category of patients with refusal from carrying out photodynamic therapy with absence of therapeutic effect and possible development of complications, associated with said therapy.
2 ex, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR MULTIMODAL DIFFERENTIAL DIAGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND VITELLIFORM DYSTROPHIES | 2021 |
|
RU2765014C1 |
| METHOD FOR MULTIMODAL DIFFERENTIAL DIAGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND VITELLIFORM DYSTROPHIES IN ADULT PATIENTS | 2021 |
|
RU2765015C1 |
| DIFFERENTIAL DIAGNOSIS METHOD FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND VITELLIFORM DYSTROPHY IN ADULT PATIENTS | 2021 |
|
RU2758679C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY AND VITELLIFORM DYSTROPHIES | 2021 |
|
RU2765016C1 |
| METHOD FOR CENTRAL SEROUS CHORIORETINOPATHY THERAPY | 2016 |
|
RU2629804C1 |
| METHOD OF DIFFERENTIATED APPROACH TO SURGICAL TREATMENT OF CHRONIC FORM OF CENTRAL SEROUS CHORIORETINOPATHY | 2024 |
|
RU2823160C1 |
| METHOD OF CENTRAL SEROUS CHORIORETINOPATHY TREATMENT | 2022 |
|
RU2797276C1 |
| METHOD OF LASER TREATMENT OF CHRONIC RECURRENT CENTRAL SEROUS CHORIORETINOPATHY | 2018 |
|
RU2682496C1 |
| PROGNOSIS METHOD FOR EFFECTIVENESS OF SUBTHRESHOLD MICRO-PULSE LASER TREATMENT OF COMPLICATED FORM OF SCLEROGENIC MACULAR DEGENERATION | 2021 |
|
RU2758661C1 |
| METHOD FOR DETERMINING THE TACTICS OF LASER TREATMENT OF ACUTE AND CHRONIC CENTRAL SEROUS CHORIORETINOPATHY | 2018 |
|
RU2674382C1 |
